Engineered immune cells take on Cancer-Related fluid swelling

NCT ID NCT07561437

Recruiting now Disease control Sponsor: Base Therapeutics (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment called NK521 for people with advanced solid tumors that have spread and caused fluid buildup in the belly (malignant ascites). The treatment uses a person's own natural killer (NK) cells that have been gene-edited to better attack cancer. The study will enroll 18 adults who have tried at least two standard treatments without success. The main goal is to check safety, but researchers will also look for signs that the treatment controls the cancer or reduces the need for fluid drainage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gene-edited natural killer (NK) cells
What this could lead to: If successful, this could point toward a new way to control malignant ascites and improve quality of life in people with advanced solid tumors.
What could go wrong: This is a very early, small Phase 1 trial with only 18 participants, so it is primarily testing safety. The treatment may not shrink tumors or control ascites, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates